<DOC>
	<DOCNO>NCT01385371</DOCNO>
	<brief_summary>This study evaluate efficacy safety grass sublingual tablet ( SCH 697243 ) versus placebo treatment grass pollen-induced allergic hayfever symptom . Participants receive either sublingual grass tablet placebo tablet study . It expect participant receive active sublingual grass tablet less hayfever symptom need less medication treat hayfever symptom grass pollen season .</brief_summary>
	<brief_title>A Study SCH 697243 Participants With Grass Pollen Allergy Symptoms , With Without Asthma ( P08067 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<criteria>Must clinical history significant allergic rhinoconjunctivitis grass ( without asthma ) Must positive skin prick test response Phleum pratense ( Timothy grass ) Must positive specific immunoglobulin E ( IgE ) Phleum pratense ( Timothy grass ) Must force expiratory volume 1 second ( FEV1 ) least 70 % predict value Screening Safety laboratory test vital sign conduct Screening Visit must within normal limit clinically acceptable investigator/sponsor Has clinical history symptomatic seasonal allergic rhinitis and/or asthma due another allergen potentially overlap GPS Has clinical history significant symptomatic perennial allergic rhinitis and/or asthma due allergen participant regularly expose Has receive immunosuppressive treatment within 3 month prior Screening Visit Has clinical history severe asthma Has history anaphylaxis cardiorespiratory symptom Has history selfinjectable epinephrine use Has history chronic urticaria angioedema Has clinical history chronic sinusitis 2 year prior Screening Visit Has current severe atopic dermatitis Is breastfeed , pregnant , intend become pregnant Had previous treatment immunotherapy grass pollen allergen 1 month within 5 year prior Screening Visit Ongoing treatment specific immunotherapy time Screening Visit Has know history allergy , hypersensitivity intolerance ingredient study drug ( except Phleum pratense ) , rescue medication , selfinjectable epinephrine Has clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study . Specific example include limited hypertension treat beta blocker , coronary artery disease , arrhythmia , stroke , ocular condition require topical beta blocker , condition require use beta blocker Has use investigational drug within 30 day Screening Visit Is participate clinical study Is family member investigational study staff conduct study Is unable meet medication washout requirement Is unlikely able complete trial , reason , likely travel extend period time GPS , opinion investigator compromise data Has clinically significant abnormal vital sign laboratory value would preclude participation study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>